Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lifei Qingchang Granules (LFQC) is a traditional Chinese medicine (TCM) formula developed as an in-hospital preparation by The First Affiliated Hospital of Guangzhou Medical University for the treatment of bronchiectasis. Adapted from the classic Yueju Pill and Dachaihu Decoction, the formulation consists of ten natural herbal and mineral components, including Gardenia jasminoides, Scutellaria baicalensis, and Rheum officinale. LFQC is designed to reduce airway inflammation by inhibiting the formation of neutrophil extracellular traps (NETs) and targeting the NOX2/p47phox signaling pathways. It is currently being evaluated in Phase 2 clinical trials for its efficacy in improving respiratory symptoms and quality of life in adult patients with stable bronchiectasis, as well as preventing acute exacerbations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lifei Qingchang Granules.